^
Association details:
| Biomarker: | NF1 mutation + CDKN2A deletion + CDKN2B deletion + MTAP deletion |
|---|---|
| Cancer: | Neurofibrosarcoma |
| Drug: | navlimetostat (BMS‐986504) (PRMT5 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Published date:
11/01/2023
Excerpt:
A 45-year-old male was diagnosed with MPNST...Genetic analysis shows NF1 splice-site 1063 mutated, CDKN2A/B/MTAP loss….The first restaging scan after 2 cycles showed stable disease with a 16.7% decrease of target lesions. Restaging after 4 cycles demonstrated an unconfirmed partial response with a 38.9% decrease of target lesions (Fig. 6).
DOI:
https://doi.org/10.1158/2159-8290.CD-23-0669